Inventiva (DB:6IV) - Stock Price, News & Analysis

6IV Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. More details

6IV fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 47.46% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Inventiva S.A. Competitors

Heidelberg Pharma

XTRA:HPHA

€105.8m

Formycon

XTRA:FYB

€857.2m

2invest

XTRA:2INV

€62.7m

Biotest

XTRA:BIO3

€1.3b

Price History & Performance

Summary of all time highs, changes and price drops for Inventiva
Historical stock prices
Current Share Price	€2.39
52 Week High	€4.21
52 Week Low	€1.45
Beta	0.80
11 Month Change	0%
3 Month Change	8.39%
1 Year Change	-37.60%
33 Year Change	-79.50%
5 Year Change	n/a
Change since IPO	-79.78%

Recent updates

Shareholder Returns

	6IV	DE Biotechs	DE Market
7D	-6.8%	-1.1%	1.1%
1Y	-37.6%	-18.8%	7.2%

Return vs Industry: 6IV underperformed the German Biotechs industry which returned -18.3% over the past year.

Return vs Market: 6IV underperformed the German Market which returned 8.6% over the past year.

Price Volatility

Is 6IV's price volatile compared to industry and market?
6IV volatility
6IV Average Weekly Movement	15.2%
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6IV's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6IV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2011	123	Frederic Cren	www.inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

Inventiva S.A. Fundamentals Summary

How do Inventiva's earnings and revenue compare to its market cap?
6IV fundamental statistics
Market cap	€214.21m
Earnings (TTM)	-€104.19m
Revenue (TTM)	€19.28m

11.1x

P/S Ratio

-2.1x

P/E Ratio

Is 6IV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6IV income statement (TTM)
Revenue	€19.28m
Cost of Revenue	€1.08m
Gross Profit	€18.19m
Other Expenses	€122.38m
Earnings	-€104.19m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 26, 2025

Earnings per share (EPS)	-1.20
Gross Margin	94.38%
Net Profit Margin	-540.52%
Debt/Equity Ratio	-85.6%

How did 6IV perform over the long term?

See historical performance and comparison

6IV Stock Overview

Rewards

Risk Analysis

Inventiva S.A. Competitors

XTRA:HPHA

€105.8m

XTRA:FYB

€857.2m

XTRA:2INV

€62.7m

XTRA:BIO3

€1.3b

Price History & Performance

Recent News & Updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Recent updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Full year 2023 earnings released: €2.44 loss per share (vs €1.31 loss in FY 2022)

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

First half 2023 earnings released: €1.32 loss per share (vs €0.72 loss in 1H 2022)

New major risk - Negative shareholders equity

New major risk - Financial position

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Full year 2022 earnings released: €1.31 loss per share (vs €1.27 loss in FY 2021)

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

First half 2022 earnings released: €0.72 loss per share (vs €0.60 loss in 1H 2021)

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.29 loss in 2Q 2020)

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

First quarter 2021 earnings released: €0.23 loss per share (vs €0.23 loss in 1Q 2020)

Full year 2020 earnings released: €0.99 loss per share (vs €1.29 loss in FY 2019)

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

New 90-day high: €12.92

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

New 90-day high: €11.34

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

First half earnings released